Is CBN legal in Slovenia?

Formal status

Across the EU, cannabinol is treated as an unauthorised novel food under Regulation (EU) 2015/2283 in the same way as CBD, and no Union list authorisation exists in any member state. Slovenia's medicines agency applies that view to all products containing added cannabinoids, and treats synthetically produced cannabinoids the same way.

Cannabinol is not named in Slovenian law. It appears nowhere in the Decree on the classification of illicit drugs - every apparent match in the schedules is a different compound word, such as dimethylheptyltetrahydrocannabinol or the several hexahydrocannabinol entries added between 2023 and 2025.

What catches it is the same material-based entry that catches CBD. Entry 112 of the decree places cannabis in Group II, covering the plant, its resin and its extracts, with no THC threshold and no quantitative carve-out. Because the entry is written around the plant material rather than around any particular cannabinoid, an extract falls within it regardless of which cannabinoid it is sold for. Group II substances may be traded only for medical, veterinary, teaching and scientific-research purposes and only with ministerial authorisation, and the criminal offence carries one to ten years.

The medical cannabis act of August 2025 reinforces this reading: it defines cannabis for medical purposes to include extracts and other naturally occurring cannabinoids regardless of THC content, and excludes the plant and its parts grown for food and industrial purposes but not extracts.

Do we sell here?

No.

No, we do not ship to Slovenia. Slovenian law does not mention cannabinol at all - it appears nowhere in the country's drug schedules, and neither does cannabidiol.

The obstacle is written around the plant rather than around any single cannabinoid. Slovenia lists cannabis extracts among its controlled drugs, with no THC threshold and no exception for low-strength preparations, so an extract is caught whichever cannabinoid it is sold for. A medical cannabis act that took effect in August 2025 confirms this reading, covering extracts and naturally occurring cannabinoids regardless of THC content.

See our CBD page for Slovenia for the fuller picture, including the real tension between how the rule is written and how Slovenian authorities actually apply it.

Outlook

Cannabinol has no independent Slovenian story and will follow whatever happens to cannabis extracts as a category. The question that would move it is the same one set out on our CBD page: whether the extract entry can lawfully be applied to a low-THC product made elsewhere in the European Union.

One trend is worth watching in its own right. Slovenia has added semi-synthetic and minor cannabinoids to its most restricted group repeatedly and quickly - in November 2023, July 2025 and again in November 2025, covering more than thirty substances. Cannabinol is not among them and nothing suggests it is a candidate, but the mechanism is well used and moves faster than any food-law process.

Timeline

May 2012

Vrhovno sodišče RS, Sklep X Ips 17/2012: "Navedene določbe dajejo jasen odgovor, da je promet s substanco, ki je opredeljena v seznamu iz Uredbe, prepovedan ne glede na obliko in količino, v kateri je dana v promet, razen v zakonsko določenih primerih." The judgment's own footnote cites I Ips 157/2008 and I Ips 158/2008 (27 November 2008) and I Ips 138/2006 (28 June 2007) for the proposition that any cannabis listed in the decree is a prohibited drug regardless of THC content. Note: the decision is a sklep rejecting revision as inadmissible, and was decided when cannabis sat in Skupina I.

Vrhovno sodišče RS, ECLI:SI:VSRS:2012:X.IPS.17.2012

November 2019

Uredba o razvrstitvi prepovedanih drog (Ur. l. RS 69/19), adopted 21 November 2019, published 22 November 2019 and in force 7 December 2019, places cannabis in Skupina II at entry 112: "KONOPLJA — Cannabis sativa L. — ekstrakti / rastlina / smola". The entry carries no THC threshold and no quantitative carve-out. Made under ZPPPD, whose article 7(2) permits Group II trade only for medical, veterinary, teaching and scientific-research purposes and whose article 10(1) requires ministerial authorisation. Amended through Ur. l. RS 157/20, 162/21, 8/23, 113/23, 50/25 and 92/25 without change to entry 112 beyond a footnote cross-referring to ZKMZN.

Uradni list RS št. 69/2019

February 2020

Višje sodišče v Mariboru, Sodba II Kp 5584/2016, in a cross-border online drug-sales case: "iz katere države in v katero državo je bila droga dostavljena, pa ni odločilna, saj je prodaja prepovedane droge izvršena že s sporazumom med kupcem in prodajalcem glede količine in cene in se za izvršitev zakonskih znakov kaznivega dejanja tudi ne zahteva, da je bilo blago izročeno kupcu", applying the territoriality principle and the ubiquity theory in KZ-1 article 19. On this reasoning a foreign seller's exposure crystallises when the order is accepted, not when the parcel is dispatched.

Višje sodišče v Mariboru, ECLI:SI:VSMB:2020:II.KP.5584.2016

November 2020

The Court of Justice of the European Union gives judgment in C-663/18 (Kanavape), holding that a Member State may not prohibit the marketing of CBD lawfully produced in another Member State where it is extracted from the Cannabis sativa plant in its entirety. Slovenia's Health Inspectorate records the judgment in its 2020 annual report as a "prelomna sodba", and its 2019 CBD inspection campaign does not resume in any subsequent reporting year.

Court of Justice of the European Union, C-663/18

August 2025

Zakon o konoplji za medicinske in znanstvene namene (ZKMZN, Ur. l. RS 60/25), published 5 August 2025 and in force 20 August 2025. Article 2(6) defines cannabis for medical purposes to include "ekstrakte iz konoplje… ne glede na vsebnost tetrahidrokanabinola (THC), kot tudi… ostali kanabinoidi naravnega izvora". Article 3(1) excludes the plant and its parts grown from catalogue varieties for food and industrial purposes, but not extracts. Article 2(16) redefines import to expressly include inbound movement "iz držav članic Evropske unije", abandoning ZPPPD's customs-territory anchor. It repeals and amends nothing in ZPPPD.

Uradni list RS št. 60/2025

June 2026

ZIRS orders a recall of "CBD kapljice, 1000 mg, 10 %" (Agrosloven z.o.o., Golnik; distributed by Be Healthy d.o.o., Šenčur), triggered by a RASFF notification, on the ground that "prisotnost THC (292,5 mg/kg) v zadevnem prehranskem dopolnilu, lahko predstavlja tveganje za zdravje ljudi". Both producer and distributor are Slovenian-established. The objection was the THC content, not the CBD or the product's novel-food status — and a Slovenian producer had been openly selling a 10% CBD oral supplement until this point.

Zdravstveni inšpektorat RS — Nevarni in neskladni izdelki